Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

ABI-008 Trial in Patients With Metastatic Breast Cancer

13 de novembro de 2019 atualizado por: Celgene

A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Metastatic Breast Cancer

To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-008 giver every 3 weeks; to characterize the toxicities of ABI-008; and to determine the pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule to patients with metastatic breast cancer.

Visão geral do estudo

Status

Rescindido

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Antecipado)

85

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • University of Texas M.D. Anderson Cancer Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

Phase I Study

Each subject must meet the following criteria to be enrolled in this study.

  1. Pathologically confirmed adenocarcinoma of the breast with metastasis.
  2. No more than 2 prior chemotherapy regimen for metastatic breast cancer. Patient should have received anthracycline and may have received a taxane but not within 6 months for registration on the study.
  3. Patient may have measurable or evaluable disease.
  4. Patient may have non-measurable bone only disease.
  5. At least 4 weeks since prior cytotoxic chemotherapy. Patients should have recovered from all acute effects of such therapy.
  6. At least 4 weeks since radiotherapy, with full recovery.
  7. At least 4 weeks since recovery from major surgery, with full recovery.
  8. ECOG performance status 0-2.
  9. Age ≥18 years.
  10. Patient must have the following blood counts at Baseline:

    • WBC > 3.0 x 109 cells/L;
    • ANC ≥ 1.5 x 109 cells/L;
    • Platelets ≥ 100 x 109 cells/L;
    • Hgb ≥ 9 grams/dL.
  11. Patient has the following blood chemistry levels at Baseline:

    • AST (SGOT), ALT (SGPT) ≤ 1.5x upper limit of normal range (ULN);
    • Total Bilirubin < ULN;
    • Alkaline phosphatase ≤ 2.5x ULN (unless bone metastasis is present in the absence of liver metastasis);
    • Creatinine ≤ 1.5 mg/dL.
  12. Peripheral neuropathy Grade 0 or stable Grade 1, by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0.
  13. If female of childbearing potential, serum pregnancy test is negative (within 72 hours of the first dose of study drug).
  14. If fertile, the patient agrees to use an effective method to avoid pregnancy for the duration of the study.
  15. Life expectancy should be ≥ 3 months.
  16. Informed consent document has been obtained stating that the patient understands the investigational nature of the proposed treatment.
  17. If obese, a patient must be treated with doses calculated using his/her actual body surface area (BSA) (the physician must be comfortable treating at the full BSA dose regardless of BSA).

Phase II Study

  1. Pathologically confirmed adenocarcinoma of the breast with metastasis.
  2. Patients should have not received prior chemotherapy for their metastatic disease. If a taxane is used as adjuvant or neoadjuvant therapy, at least 12 months should have elapsed from the date of the last dose.
  3. Patient must have at least one measurable metastatic lesion.
  4. At least 4 weeks since prior cytotoxic chemotherapy. Patients should have recovered from all acute effects of such therapy.
  5. At least 4 weeks since radiotherapy, with full recovery.
  6. At least 4 weeks since major surgery, with full recovery.
  7. ECOG performance status 0-2.
  8. Age ≥18 years.
  9. Patient must have the following blood counts at Baseline:

    • WBC > 3.0 x 109 cells/L;
    • ANC ≥ 1.5 x 109 cells/L;
    • Platelets ≥ 100 x 109 cells/L;
    • Hgb ≥ 9 grams/dL.
  10. Patient has the following blood chemistry levels at Baseline:

    • AST (SGOT), ALT (SGPT) ≤ 1.5x upper limit of normal range (ULN);
    • Total Bilirubin < ULN;
    • Alkaline phosphatase ≤ 2.5x ULN (unless bone metastasis is present in the absence of liver metastasis);
    • Creatinine ≤ 1.5 mg/dL.
  11. Peripheral neuropathy Grade 0 or stable Grade 1, by NCI CTCAE v3.0.
  12. If female of childbearing potential, serum pregnancy test is negative (within 72 hours of the first dose of study drug).
  13. If fertile, the patient agrees to use an effective method to avoid pregnancy for the duration of the study.
  14. Life expectancy should be ≥ 3 months.
  15. Informed consent document has been obtained stating that the patient understands the investigational nature of the proposed treatment.

Exclusion Criteria:

Phase I Study

Subjects who meet any of the following criteria will be excluded from the study.

  1. Concurrent therapy (chemotherapy, hormonal therapy, kinase inhibitors, immunotherapy, etc) for breast cancer. Bisphosphonates are allowed.
  2. Parenchymal brain metastases, unless documented to be clinically and radiographically stable for at least 6 months after treatment.
  3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  4. Patients with significant cardiovascular disease including congestive heart failure (New York Heart Association Class III or IV), active angina pectoris or recent myocardial infarction (within the last 6 months).
  5. History of other malignancy within the last 5 years which could affect the diagnosis or assessment of breast cancer excluding non-melanomatous skin cancer and cervical carcinoma in situ.
  6. Patients who have received an investigational drug within the previous 4 weeks.
  7. Patient is currently enrolled in any other clinical study in which investigational procedures are performed or investigational therapies are administered. A patient may not enroll in such clinical trials while participating in this study.
  8. Pregnant or nursing women.
  9. Patients with history of allergic reactions attributed to solvent-based docetaxel(Taxotere).
  10. ECOG performance status 3-4.
  11. Because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with docetaxel. Appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated.

Phase II Study

Subjects who meet any of the following criteria will be excluded from the study.

  1. Prior neo-adjuvant or adjuvant chemotherapy is allowed. If a taxane was part of the adjuvant regimen, at least 12 months should have transpired since completion of taxane regimen.
  2. Concurrent therapy (chemotherapy, hormonal therapy, kinase inhibitors, immunotherapy, etc) for breast cancer.
  3. Parenchymal brain metastases, unless documented to be clinically and radiographically stable for at least 6 months after treatment.
  4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  5. Patients with significant cardiovascular disease including congestive heart failure (New York Heart Association Class III or IV), active angina pectoris or recent myocardial infarction (within the last 6 months).
  6. History of other malignancy within the last 5 years which could affect the diagnosis or assessment of breast cancer excluding non-melanomatous skin cancer and cervical carcinoma in situ.
  7. Patients who have received an investigational drug within the previous 4weeks.
  8. Patient is currently enrolled in any other clinical study in which investigational procedures are performed or investigational therapies are administered.
  9. Pregnant or nursing women.
  10. Patients with history of allergic reactions attributed to solvent-based docetaxel(Taxotere).
  11. ECOG performance status 3-4.
  12. Because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with docetaxel.
  13. Patients with tumor overexpression of HER2/neu.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Prazo
To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-008 giver every three weeks.
Prazo: End of Study (EOS) and Follow Up
End of Study (EOS) and Follow Up

Medidas de resultados secundários

Medida de resultado
Prazo
To evaluate the safety and tolerability of ABI-008 in the metastatic breast cancer patient population; and to determine the pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule.
Prazo: End of Study (EOS) and Follow Up
End of Study (EOS) and Follow Up

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Nuhad Ibrahim, MD, M.D. Anderson Cancer Center

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de novembro de 2007

Conclusão Primária (Real)

1 de dezembro de 2008

Conclusão do estudo (Real)

1 de dezembro de 2008

Datas de inscrição no estudo

Enviado pela primeira vez

14 de setembro de 2007

Enviado pela primeira vez que atendeu aos critérios de CQ

14 de setembro de 2007

Primeira postagem (Estimativa)

18 de setembro de 2007

Atualizações de registro de estudo

Última Atualização Postada (Real)

14 de novembro de 2019

Última atualização enviada que atendeu aos critérios de controle de qualidade

13 de novembro de 2019

Última verificação

1 de novembro de 2019

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever